Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy

Sponsor
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Study ID
NCT06858345
Status
Recruiting
Apply to this trial

Conditions

  • Preeclampsia

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The pharmacological treatment strategy is then tailored to the underlying hemodynamic phenotype of each patient. That is, rather than applying a one-size-fits-all treatment for all patients, therapy is tailored to the specific characteristics of how the cardiovascular system functions in each patient (e.g., whether the problem is more related to blood volume, vascular resistance, cardiac output, etc.). The goal is to personalize therapy to more effectively treat hypertensive states of pregnancy.

Key Dates

First listed
Mar 5, 2025
Start date
Jan 1, 2025
Status verified
Feb 2025
Primary completion
Jan 15, 2026
Completion
Jan 15, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: • Duration of gestation in pregnancy complicated by hypertensive state of pregnancy with antihyperte
    • Duration of gestation in pregnancy complicated by hypertensive state of pregnancy with antihypertensive therapy guided by hemodynamic phenotypes

Primary Outcome Measure

Prolongation of at least one week of gestation in pregnancy complicated by hypertensive state of pregnancy with antihypertensive therapy guided by hemodynamic phenotypes [ Time Frame: Up to 40 weeks ]

Central Contacts

Related Studies